| 1. |
|
|
| 2. |
- Ruilope, LM, et al.
(author)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Journal article (peer-reviewed)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 3. |
|
|
| 4. |
-
- 2019
-
Journal article (peer-reviewed)
|
|
| 5. |
- Beal, Jacob, et al.
(author)
-
Robust estimation of bacterial cell count from optical density
- 2020
-
In: Communications Biology. - : Springer Science and Business Media LLC. - 2399-3642. ; 3:1
-
Journal article (peer-reviewed)abstract
- Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data.
|
|
| 6. |
- Saah, Tammy C., et al.
(author)
-
Chapter 106: Anxiolytic drugs
- 2015
-
In: Psychiatry Fourth Edition. - 9781118845479 ; 2, s. 2159-2192
-
Book chapter (peer-reviewed)
|
|
| 7. |
- Treede, Rolf-Detlef, et al.
(author)
-
A classification of chronic pain for ICD-11.
- 2015
-
In: Pain. - : Ovid Technologies (Wolters Kluwer Health). - 0304-3959 .- 1872-6623. ; 156:6, s. 1003-1007
-
Journal article (peer-reviewed)
|
|
| 8. |
- Treede, Rolf-Detlef, et al.
(author)
-
Chronic pain as a symptom or a disease : the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).
- 2019
-
In: Pain. - : Ovid Technologies (Wolters Kluwer Health). - 0304-3959 .- 1872-6623. ; 160:1, s. 19-27
-
Journal article (peer-reviewed)abstract
- Chronic pain is a major source of suffering. It interferes with daily functioning and often is accompanied by distress. Yet, in the International Classification of Diseases, chronic pain diagnoses are not represented systematically. The lack of appropriate codes renders accurate epidemiological investigations difficult and impedes health policy decisions regarding chronic pain such as adequate financing of access to multimodal pain management. In cooperation with the WHO, an IASP Working Group has developed a classification system that is applicable in a wide range of contexts, including pain medicine, primary care, and low-resource environments. Chronic pain is defined as pain that persists or recurs for more than 3 months. In chronic pain syndromes, pain can be the sole or a leading complaint and requires special treatment and care. In conditions such as fibromyalgia or nonspecific low-back pain, chronic pain may be conceived as a disease in its own right; in our proposal, we call this subgroup "chronic primary pain." In 6 other subgroups, pain is secondary to an underlying disease: chronic cancer-related pain, chronic neuropathic pain, chronic secondary visceral pain, chronic posttraumatic and postsurgical pain, chronic secondary headache and orofacial pain, and chronic secondary musculoskeletal pain. These conditions are summarized as "chronic secondary pain" where pain may at least initially be conceived as a symptom. Implementation of these codes in the upcoming 11th edition of International Classification of Diseases will lead to improved classification and diagnostic coding, thereby advancing the recognition of chronic pain as a health condition in its own right.
|
|
| 9. |
- Cardeña, Etzel, et al.
(author)
-
Dissociative disorders measures
- 2008
-
In: Handbook of psychiatric measures. (2. ed). - 9781585622184 ; , s. 587-599
-
Book chapter (other academic/artistic)abstract
- Dissociation is a complex concept that involves at least two different types of phenomena: the compartmentalization of psychological processes such as memory or identity that should ordinarily be integrated, and alterations of consciousness characterized by experiential detachment from the self and/or the environment. Although there are non-pathological manifestations of dissociation, this chapter covers measures for the detection of pathological dissociation and for the diagnosis of the DSM-IV dissociative disorders (dissociative amnesia, dissociative fugue, dissociative identity disorder, depersonalization disorder, and dissociative disorder not otherwise specified). The instruments included in this section evaluate clinical and non-clinical dissociation (e.g., the Dissociative Experiences Scale [DES]) and help diagnose dissociative disorders according to DSM-IV criteria (e.g., the Dissociative Disorders Interview Schedule [DDIS]).
|
|
| 10. |
- Edwards, Deidre M., et al.
(author)
-
Anxiolytic Drugs
- 2008
-
In: Psychiatry. - Chichester, UK : John Wiley & Sons, Ltd. - 9780470065716 ; , s. 2223-2253
-
Book chapter (other academic/artistic)abstract
- This chapter provides a brief history of the evolution of medications used to treat anxiety and anxiety disorders, as described in the Diagnostics and Statistical Manual of Mental Disorders (DSM-IV-TR). We also summarize the efficacy and adverse effects data from clinical trials for these medications. Medication classes reviewed include antidepressants, benzodiazepines, beta-blockers, anticonvulsants, and antipsychotics. Treatment outcomes and clinical implications are reviewed for each of the individual medication classes.
|
|
